Lipid mediator biosynthesis pathways

"Lipid mediator biosynthesis pathways" refers to the series of enzymatic processes by which cells generate bioactive lipid molecules—such as prostaglandins, leukotrienes, platelet activating factor, lysophosphatidic acid, sphingosine 1-phosphate, and endocannabinoids—from membrane phospholipids or other precursors. These mediators are produced locally in response to extracellular stimuli and act primarily through G protein-coupled receptors to regulate inflammation, immunity, vascular tone, hemostasis, pain perception, and other physiological processes. The key enzymes involved include cyclooxygenases (COX), lipoxygenases (LOX), phospholipase A2 (PLA2), among others. Dysregulation of these pathways is implicated in a wide range of diseases including chronic inflammation and cancer. However, "lipid mediator biosynthesis pathways" is not itself a molecular target but rather describes multiple interconnected metabolic routes; thus it cannot be classified as an individual therapeutic target such as a receptor or enzyme. "Lipid mediators exert their biological effects by binding to cognate receptors... They are produced by multistep enzymatic pathways..." "‘Lipid mediators’ represent a class of bioactive lipids that are produced locally through specific biosynthetic pathways..." Note: This entry does not correspond to a single molecule or druggable target but rather encompasses multiple enzymes and signaling molecules within complex metabolic networks. For structured data on actual targets within these pathways—such as cyclooxygenase 2 (COX2/PTGS2), 5-lipoxygenase (ALOX5), or specific GPCRs for lipid mediators—each should be listed individually.

Other names

Lipid mediator biosynthetic pathwaysLipid mediator synthesis pathwaysPathways of lipid mediator biosynthesis